Minimal Residual Disease (MRD) Testing

Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials

Genetron Health Nabs CE Mark for Blood Cancer Residual Disease Test Kit

Natera Minimal Residual Disease Test Value Called Into Question by City of Hope CRC Patient Data

Personalis, UCSD Cancer Center Ink Clinical Genomic Testing, Research Partnership

NeoGenomics Blood-Based Minimal Residual Disease Test Receives CE Mark

C2i Genomics, OncoDNA Enter Strategic Alliance for AI-Based Cancer Detection, Monitoring

Sequencing-Based MRD Detection in Bone Marrow May Predict ALL Relapse After CAR T-Cell Therapy

Postsurgical ctDNA Analysis Predicts Adjuvant Chemotherapy Benefit in NSCLC

Palmetto Finalizes Medicare Coverage for MRD Cancer Testing

Genetron Health, Fosun Ink Commercialization Deal for Seq-MRD Test in China